MedTrace Logo

Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB

NCT01166230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 551

Last updated 2019-04-09

Study results available
· View outcomes & findings →

Summary

The study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will lead to a longer-term reduction in recurrences compared to standard white light cystoscopy/TURB.

Conditions

Sponsors & Collaborators

  • Photocure

    lead INDUSTRY

Principal Investigators

  • Herbert Barton Grossman, MD · The University of Texas MD Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States
  • Austria
  • Canada
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01166230 on ClinicalTrials.gov